Human IgA抗体;Human IgA Antibody—艾普蒂 新品

+ +

•  

   

     Microtiter wells were coated with human immunoglobulins with various isotypes. P15001 was used as the primary antibody and peroxidase conjugated goat anti-mouse IgG was used as the secondary antibody. Result: P15001 does not cross-react with human IgG1, IgG2, IgG3, IgG4, IgM and IgE.    

  
  

•  

   

     Lane 1: 100 ng of human IgA;  Lane 2: 100 ng of human IgM;  Lane 3: 100 ng of human IgG;Lane 4: 100 ng of human IgE;  Result: P15001 can specifically detect human IgA by Western blotting.    

  
  

•  

   

     IHC-P analysis of tonsil tissue by IgA antibody (P15001) IHC-P was performed using sections of the formalin-fixed paraffin-embedded tonsil tissue;Result: Germinal center cells and squamous epithelial cells are positively stained at the cytoplasm.    

  
  

Human immunoglobulin A (IgA) is a critical antibody class in mucosal immunity, constituting 10-15% of total immunoglobulins in circulation. It exists in two primary forms: monomeric IgA1 (80-90% of serum IgA) and polymeric IgA2. which dominates mucosal secretions. A unique feature is secretory IgA (sIgA), formed when polymeric IgA binds the polymeric immunoglobulin receptor (pIgR) on epithelial cells, enabling transcytosis into mucosal surfaces like the gut, respiratory tract, and breast milk. This process adds a secretory component that protects sIgA from enzymatic degradation.

As the first-line defense at mucosal barriers, IgA neutralizes pathogens, blocks microbial adhesion, and facilitates antigen removal via "immune exclusion" without triggering inflammation. It maintains gut homeostasis by shaping microbiota composition through glycan-mediated interactions. While serum IgA1 mainly originates from bone marrow, mucosal IgA2 is predominantly produced by plasma cells in lamina propria under gut-associated lymphoid tissue (GALT) regulation.

IgA deficiencies (partial or total) affect 1:600 people, often asymptomatic but linked to increased respiratory/gut infections. Conversely, aberrant IgA responses contribute to pathologies like IgA nephropathy (IgAN), where galactose-deficient IgA1 forms immune complexes damaging kidney glomeruli. Its short serum half-life (5-6 days) contrasts with prolonged mucosal persistence, highlighting dual roles in systemic and local immunity. Current research explores IgA's therapeutic potential in microbiome modulation and mucosal vaccine design.